Black Diamond Therapeutics, Inc. (NASDAQ:BDTX – Get Rating) – Equities research analysts at Wedbush increased their FY2027 earnings per share estimates for shares of Black Diamond Therapeutics in a research note issued on Tuesday, May 9th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings of $0.22 per share for the year, […]
Black Diamond Therapeutics (NASDAQ:BDTX – Get Rating) and Alector (NASDAQ:ALEC – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, dividends, risk and institutional ownership. Risk and Volatility Black Diamond Therapeutics has a beta […]
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX – Get Rating) shares were down 5% during mid-day trading on Tuesday . The company traded as low as $1.45 and last traded at $1.51. Approximately 34,809 shares changed hands during mid-day trading, a decline of 68% from the average daily volume of 107,811 shares. The stock had previously closed […]
Black Diamond Therapeutics (NASDAQ:BDTX – Get Rating) and La Jolla Pharmaceutical (NASDAQ:LJPC – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends. Volatility & Risk Black Diamond Therapeutics has […]
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX – Get Rating) major shareholder Growth N. V. Biotech acquired 150,000 shares of the business’s stock in a transaction on Monday, April 18th. The shares were purchased at an average cost of $3.29 per share, for a total transaction of $493,500.00. Following the completion of the acquisition, the insider now […]